Kuro , et al i received a msg from a mate re my last post that I quickly framed in response to your expectations call for maybe an ann monday! Asking me if i’d turned unhappy ? far from it it just that when investing in bio medical space we all need to be patient new news just cant be expected to unfold every week!
In reflection , lets look at where we were last year and where we are now and the steps the company has taken on leading us down this yellow brick road- this time last year the objective was clear and focussed- to provide the world with a breakthrough drug to meet the urgent and unmet need for defeating quickly and cheaply the terrible morbidity associated with sepsis the company is now on the cusp of commencing first in human trials of recce327 to demonstrate that to all under fda guidlines
as the journey from last year unfolded, we were told that further and wider opportunities were opening up in the application of the drug to address MR. Bacteria in gonnoreah and UTI as shown in the companies pre clinical tests
then we heard that the company had explored recce327’s application to meeting dire bacterial infection issues involving burns and open wounds to the skin. now already we here - in the recent 4c we were told that first in human trials are imminent in a leading hospital in WA! in addition the company has rapidly moved to seek out the application of recce 327 and a new special version of the drug recce529 in meeting the urgent need for a covid19 therapy - third party tests are already underway in the usa and csiro in victoria
these are giant strides along the road!
indeed any drug company achieving just one of these applications with a positive outcome would see it as a “ company maker”! recce has now five fronts in which recce 327 and recce 529 could be weaponised to achieve these serious and urgent unmet needs these are very very significant achievements in a very short time and hold huge opportunities for investors in the company
We just cant expect new news to be out every week! we have been spoiled by what has been achieved in just the past year- the rest of this year and next clearly holds great promise to further meet and indeed again exceed shareholder expectations
if we do indeed see further announcements very soon on the commencement of topical applications of the drug that will without doubt fuel further investor excitement and resultant revaluation of the company recent posts re speculation and hyperbole as to a $10 share price needs to be placed in a rational valuation framework and timeframe for success - and then degree of market adaption and penetration globally but yes those sort of valuations are possible if as they say everything works out to perfection! but in the meantime the company can only be applauded for taking such giant strides along the yellow brick road with all the hurdles placed in front so far all being cleared looking forward to next week too!
RCE Price at posting:
$1.31 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)